Navigation Links
Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
Date:8/6/2008

Total Drug Market for Pain Will Reach More Than $47 Billion in 2023,

According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although strong opioids and non-steroidal anti-inflammatory drugs (NSAIDs) will continue to dominate the pain market over the next 15 years, novel drug classes will claim over one-fifth of total market share by 2023.

The new special Pharmacor report entitled Novel Approaches to Pain finds that the overall pain market will reach more than $47 billion in 2023 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. From 2008 to 2013, reformulations and emerging therapies in existing drug classes will be the primary drivers of market growth while from 2013 to 2023, growth will result predominantly from the launch of innovative agents representing entirely new drug classes. Therapies representing novel drug classes will expand the pain market by adding to the eight major analgesic drug classes, creating as many as 18 drug classes by 2023, according to the report.

The most successful reformulations and emerging therapies in existing drug classes will be abuse- and dependence-resistant strong opioid formulations, including King Pharmaceuticals/Pain Therapeutics' Remoxy; as well as safer and more tolerable NSAID formulations such as NicOx's naproxcinod and AstraZeneca/POZEN's naproxen/esomeprazole combination; Johnson & Johnson's new dual-acting opioid tapentadol; and longer lasting antimigraine formulations such as GlaxoSmithKline's Treximet.

Of the novel drug classes expected to launch for pain through 2023, the calcitonin gene-related peptide receptor antagonists, growth factor modulators, and subtype-selective ion channel modulators will have the most growth impact owing to their potential efficacy advantages over existing drug classes. All three of these novel drug classes are forecast to attain blockbuster peak-year sales.

"The most commercially promising drugs with novel mechanisms of action are being developed for the treatment of chronic pain that is either inflammatory or neuropathic in origin," said Natalie Taylor, Ph.D., analyst at Decision Resources. "Current therapies for inflammatory pain, such as the NSAID drug class, are plagued by safety concerns when administered over the long-term, while current therapies for neuropathic pain, such as antidepressants and anti-epileptics, are associated with inconsistent efficacy."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Despite Bad Economy Botox Sales Are Booming
2. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
3. P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth
4. FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008
5. Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income
6. VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales
7. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
8. Milestone Scientific Expands Domestic Sales Network With Addition of Three New Dental Distributors
9. Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08
10. Longs Reports Preliminary June Retail Drug Store Sales
11. New Research Covers Current Trends and Future Directions of the High Performing Pharmaceutical District Sales Managers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , ... February 27, 2017 , ... ... Shamanic Healing and Spiritual Awakening, is happy to announce her “Spring Rejuvenation ... and body, these individual customized retreats offer the winter-weary soul an excellent opportunity ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has ... a company involved in the underground testing of nuclear weapons. Years later, when her ... Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by ...
(Date:2/27/2017)... ... 27, 2017 , ... Orange County dentist, Dr. A. Rassouli, comments ... occurs when the bacteria in plaque infect the gums and other tissues supporting the ... root planing or SRP, and can include surgical therapies if the condition has led ...
(Date:2/27/2017)... ... , ... Miro is the ultimate smart media center that offers a fascinating ... shows and much more apps for user exploration. Its innovative acoustic design with premium ... x 720 provides crisp images with remarkable clarity and color. The WiFi connection enables ...
(Date:2/27/2017)... Houston, TX (PRWEB) , ... February 27, 2017 ... ... the 75,000 customer threshold mark last week. In addition, Discount Power's RCE (Residential ... Volterra Energy LLC in March 2014. The company had 800 customers and 2,250 ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... questions: What are the key drugs marketed ... Global Hemophilia market? What are the unit prices and ...
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... Feb. 23, 2017  Directors from Pharma To Market Pty Ltd ... joined forces, resulting in the founding of Pharma To Market Pte ... To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... the Singapore based entity. Joelle brings with ...
Breaking Medicine Technology: